

Appl. No. : 09/782,816  
Filed : February 14, 2001

n and m independently represent 0 or 1, and Xaa is V or L;

X1 and X2 are independently defined as follows

X1 is GVKETPQQKYQRLLHEVQELTT (SEQ ID NO: 3), or  
VKETPQQKYQRLLHEVQELTT (SEQ ID NO: 4), or  
KETPQQKYQRLLHEVQELTT (SEQ ID NO: 5) or,  
ETPQQKYQRLLHEVQELTT (SEQ ID NO: 6) or,  
TPQQKYQRLLHEVQELTT (SEQ ID NO: 7) or,  
PQQKYQRLLHEVQELTT (SEQ ID NO: 8) or,  
QQKYQRLLHEVQELTT (SEQ ID NO: 9) or,  
QKYQRLLHEVQELTT (SEQ ID NO: 10) or,  
KYQRLLHEVQELTT (SEQ ID NO: 11) or,  
YQRLLHEVQELTT (SEQ ID NO: 12) or,  
QRLLHEVQELTT (SEQ ID NO: 13) or,  
RLLHEVQELTT (SEQ ID NO: 14) or,  
LLHEVQELTT (SEQ ID NO: 15) or,  
LHEVQELTT (SEQ ID NO: 16) or,  
HEVQELTT (SEQ ID NO: 17) or,  
EVQELTT (SEQ ID NO: 18) or,  
VQELTT (SEQ ID NO: 19) or,  
QELTT (SEQ ID NO: 20) or,  
ELTT (SEQ ID NO: 21), or  
LTT, or  
TT, or  
T;

and

X2 is AKQLAAL (SEQ ID NO: 22), or  
AKQLA (SEQ ID NO: 23), or  
AKQLA (SEQ ID NO: 24), or  
AKQL (SEQ ID NO: 25), or  
AKQ, or  
AK, or

Appl. No. : [REDACTED] 09/782,816  
Filed : February 14, 2001

A;

and

Y1 and Y2 are independently defined as follows

Y1 is GEKETPVQKCQRLQIEMNELLN (SEQ ID NO: 26), or  
EKETPVQKCQRLQIEMNELLN (SEQ ID NO: 27), or  
KETPVQKCQRLQIEMNELLN (SEQ ID NO: 28), or  
ETPVQKCQRLQIEMNELLN (SEQ ID NO: 29), or  
TPVQKCQRLQIEMNELLN (SEQ ID NO: 30), or  
PVQKCQRLQIEMNELLN (SEQ ID NO: 31), or  
VQKCQRLQIEMNELLN (SEQ ID NO: 32), or  
QKCQRLQIEMNELLN (SEQ ID NO: 33), or  
KCQRLQIEMNELLN (SEQ ID NO: 34), or  
CQRLQIEMNELLN (SEQ ID NO: 35), or  
QRLQIEMNELLN (SEQ ID NO: 36), or  
RLQIEMNELLN (SEQ ID NO: 37), or  
LQIEMNELLN (SEQ ID NO: 38), or  
QIEMNELLN (SEQ ID NO: 39), or  
IEMNELLN (SEQ ID NO: 40), or  
EMNELLN (SEQ ID NO: 41), or  
MNELLN (SEQ ID NO: 42), or  
NELLN (SEQ ID NO: 43), or  
ELLN (SEQ ID NO: 44), or  
LLN, or  
LN, or  
N; and

Y2 is VATVISTAR (SEQ ID NO: 45), or  
VATVISTA (SEQ ID NO: 46), or  
VATVIST (SEQ ID NO: 47), or  
VATVIS (SEQ ID NO: 48), or  
VATVI (SEQ ID NO: 49), or  
VATV (SEQ ID NO: 50), or

*A1 concurred*

Appl. No. : 09/782,816  
Filed : February 14, 2001  
VAT, or  
VA, or  
V, and

derivatives thereof having at least about 90% identity with SEQ ID NO: 1 or SEQ ID NO: 2.--

Please replace the paragraph beginning at page 5, line 31, with the following rewritten paragraph:

*A2*

--In a preferred embodiment, the peptide has one of the following sequences: GVKETPQQKYQRLLHEVQELTTEVEKIKTTVKESATEEKLTPVXaaLAKQLAAL (SEQ ID NO: 51), where Xaa is as defined above, or GEKETPVQKCQRLQIEMNELLNEVAALQVDRKVADEEKQSYDAVVATVISTAR (SEQ ID NO: 52), or has at least about 75%, preferably at least about 80%, more preferably at least about 85%, even more preferably at least about 90%, most preferably at least about 95% identity with one of these sequences. Preferably, the peptide variants contain only conservative amino acid substitutions compared to the reference peptide sequences.--

Please replace the paragraph beginning at page 7, line 4, with the following rewritten paragraph:

*A3*

--Figure 1 is the amino acid sequence of human p50 (SEQ ID NO: 53), wherein the peptide of SEQ ID NO: 51 (Xaa is L) is bolded and underlined.--

Please replace the paragraph beginning at page 7, line 6, with the following rewritten paragraph:

*A4*

-- Figure 2 is the partial amino acid sequence of mouse p50 (SEQ ID NO: 54), wherein the peptide of SEQ ID NO: 51 (Xaa is V) is bolded and underlined.--

In the Claims:

Please amend the claims to read as follows: